Our ambassador is previewing all five days of the Goodwood, beginning with an enthralling opening day on Tuesday, featuring the Goodwood Cup.
Scandinavia poised to retain cup crown
The eagerly anticipated re-match between SCANDINAVIA and Trawlerman in the Al Shaqab Goodwood Cup (3.35) on the opening day of the Qatar Goodwood Festival is one race I'm particularly excited about in what promises to be an amazing week on the Sussex Downs.
Paolo Maldini has left his role as technical director of the Italian Football Federation (FIGC) following the decision not to appoint Andrea Pirlo as Italy head coach, according to Sky in Italy.
Alfred Johansson is only 35, but what can be expected from Motherwell under the youngest manager in the Scottish Premiership?
The Swede is confident he can build on the success under former manager Jens Berthel Askou, following his move to Toulouse after guiding the Steelmen to a fourth-placed finish in the Premiership last season.
Y'all, the day has finally arrived. The Gordie Howe Bridge, $4.6 billion and decades in the making, finally opened Monday, July 27. It was a momentous day for everyone, especially after repeated delays caused by international trade friction. What should have been a moment of fragile unity between our two countries turned into a stand off, with Canadian Prime Minister Mark Carney refusing to blink. A particular moment of triumph that President Donald Trump couldn't stop with all his bluster? Michigan Governor Gretchen Whitmer, driving across the bridge in a Ford Mustang Convertible.
Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profile
In FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%
Enrollment initiated in Phase II trial of iadademstat in essential thrombocythemia
U.S. patent granted for vafidemstat in borderline personality disorder (BPD)
Cash position as of June 30, 2026 was $16.7 million (€14.7 million), excluding the gross proceeds of €12.0 million ($13.7 million) raised in the capital increase completed after quarter end
On July 1, 2026, the company entered into a financing agreement with COFIDES with a commitment to invest €25 million in future capital increases
MADRID and CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended June 30, 2026, and provided a corporate update on recent developments.